Research programme: tissue regeneration therapy - Nanotope

Drug Profile

Research programme: tissue regeneration therapy - Nanotope

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nanotope
  • Class
  • Mechanism of Action Angiogenesis inducing agents; Bone development stimulants; Cartilage replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone disorders; Cartilage disorders; Peripheral arterial disorders; Spinal cord injuries; Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cartilage-disorders in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top